Latest Health News

Mayne Pharma has announced the expiration of the US antitrust waiting period, a critical step forward in Cosette Pharmaceuticals' proposed acquisition. The transaction now moves closer to completion, pending other regulatory and shareholder approvals.

Boss Energy reports a successful ramp-up to commercial production at its Honeymoon uranium mine, backed by a robust $229 million cash position and promising growth at its US Alta Mesa project.

JB Hi-Fi Limited reports robust sales growth across Australia and New Zealand in Q3 FY25, maintaining momentum in a competitive retail environment.

HyTerra Limited has confirmed hydrogen concentrations up to 96.1% in its Sue Duroche 3 well in Kansas, reinforcing the potential of its natural hydrogen exploration program. Elevated helium levels were also detected, with further testing planned to assess commercial viability.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Global Uranium and Enrichment Limited has completed a scoping study for its Hansen Deposit in Colorado, revealing strong economic potential through innovative mining and beneficiation methods.

Southern Cross Media Group reports robust audio revenue growth exceeding expectations and signals a return to dividends for FY25, underpinned by disciplined cost management.

EZZ Life Science Holdings Limited has announced a fully franked ordinary dividend of AUD 0.02 per share for the six months ending December 2024, signaling steady returns for shareholders.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Biome Australia is expanding its health portfolio with Activated Therapeutics, a new practitioner-only brand launching four evidence-based natural medicine products in Q4 2025.

HMC Capital has unveiled an ambitious plan to grow its assets under management to over $50 billion within the next 3-5 years, supported by strong fundraising and diversified investment verticals. The company’s FY25 outlook remains solid, underpinned by operational growth and strategic initiatives across real estate, digital infrastructure, and energy transition.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.